[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Agenus Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":17,"phases":4,"briefSummary":18,"conditions":19,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":41,"locationsCount":4},"100573841","expanded-access-program-eap-designed-to-provide-access-to-botensilimab-and-balstilimab-before-regulatory-approval-100573841",false,"NCT06751524","Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval","Botensilimab and Balstilimab Expanded Access Program","Key Inclusion Criteria:\n\n* The patient's disease is serious or life-threatening.\n* The patient has undergone appropriate standard treatments; there are no comparable or satisfactory alternative treatments for the disease or condition; the treatment is adjunct to an existing treatment option, and the treatment is not medically contra-indicated.\n* Sufficient efficacy and safety evidence exists to make a benefit-risk analysis consistent with this policy and the potential patient benefit justifies any potential risks of treatment.\n* Sufficient clinical data are available to identify an appropriate dose and treatment duration.\n* The patient's treating physician and qualified medical personnel at Agenus agree there is sufficient evidence to assume the potential benefit to the patient justifies potential risks.\n* The patient is not eligible for participation in an ongoing clinical trial of the investigational medicine, including lack of access due to geographic limitations.\n* Expanded Access will not adversely impact any clinical development program, in particular, the conduct of a pivotal clinical trial that is required for regulatory approval.\n* The request must be made by the patient's treating physician.\n\nNote: Other defined Inclusion\u002FExclusion criteria may apply.","ALL","EXPANDED_ACCESS","This is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.",[20,21,22,23,24,25,26,27],"Colorectal Cancer (CRC)","Pancreatic Cancer","Non-Small Cell Lung Cancer (NSCLC)","Hepatocellular Carcinoma (HCC)","Melanoma","Sarcoma","Ovarian Cancer","Prostate Cancer",[29,30,31,32,33,34,35],"Compassionate Use","Early Access","Expanded Access","Managed Access","Pre-approval Access","Special Access","Named Patient Program (NPP)","AVAILABLE","2026-05-13",{"date":39,"type":40},"2026-05-15","ACTUAL",{"name":42,"class":43},"Agenus Inc.","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":17,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":64,"locationsCount":65},"100483279","expanded-access-for-cancer-treatment-with-balstilimab-agen2034-and-zalifrelimab-agen1884-100483279","NCT05572970","Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)","Expanded Access for Cancer Treatment With Balstilimab (AGEN2034), Either as Monotherapy, or as Used in Combination With Zalifrelimab (AGEN1884)","Inclusion Criteria:\n\n* Participants must have completed predicate study protocol requirements, including prior treatment duration and follow-up.\n\nExclusion Criteria:\n\n\\-","18 Years","This is an expanded access study for cancer treatment with balstilimab alone or in combination with zalifrelimab for an intermediate-size participant population. This study addresses the treatment needs of participants who have been previously and specifically treated with balstilimab alone or in combination with zalifrelimab in a clinical study, who have experienced a benefit from this treatment and\u002For wish to continue treatment, and who are eligible for treatment under this expanded access study.",[54],"Cancer",[56,57,58,59,60],"Balstilimab","AGEN2034","Zalifrelimab","AGEN1884","Monotherapy","2026-05-05",{"date":63,"type":40},"2026-05-06",{"name":42,"class":43},7,""]